Xie Y - Search Results

1

Innovative Dual mRNA-Lipid Nanoparticle Therapy Targeting CRHBP and CFHR3 for Enhanced Treatment of Hepatocellular Carcinoma.

Fu T, Zhou B, Li Y, Liu W, Xie Y, Mo Z, Yin F, Wang Y, Fang K, Fang Y, Xiong Z, Yu K, Le A. Fu T, et al. Among authors: xie y. Int J Nanomedicine. 2024 Dec 7;19:13183-13199. doi: 10.2147/IJN.S498065. eCollection 2024. Int J Nanomedicine. 2024. PMID: 39664759 Free PMC article.

2

Nanoparticles Mediated circROBO1 Silencing to Inhibit Hepatocellular Carcinoma Progression by Modulating miR-130a-5p/CCNT2 Axis.

Meng H, Li R, Xie Y, Mo Z, Zhai H, Zhang G, Liang G, Shi X, Zhou B. Meng H, et al. Among authors: xie y. Int J Nanomedicine. 2023 Mar 30;18:1677-1693. doi: 10.2147/IJN.S399318. eCollection 2023. Int J Nanomedicine. 2023. PMID: 37020690 Free PMC article.

3

Amplification of DDR2 mediates sorafenib resistance through NF-κB/c-Rel signaling in hepatocellular carcinoma.

Liu QQ, Liu YW, Xie YK, Zhang JH, Song CX, Wang JZ, Xie BH. Liu QQ, et al. Cell Biol Int. 2021 Sep;45(9):1906-1916. doi: 10.1002/cbin.11625. Epub 2021 May 16. Cell Biol Int. 2021. PMID: 33969575

4

Dipeptidyl peptidase-8 induces sorafenib resistance via binding with c-Rel to mediate NF-κB signaling in hepatocellular carcinoma.

Liu HF, Xie YK, Zhong BY, Zhang JH, Song CX, Liu YW, Yang Y, Xie BH. Liu HF, et al. Among authors: xie yk, xie bh. Cell Biol Int. 2022 Feb;46(2):213-221. doi: 10.1002/cbin.11719. Epub 2021 Dec 2. Cell Biol Int. 2022. PMID: 34719075

5

LINC02273 Promotes Hepatocellular Carcinoma Progression via Retaining β-Catenin in the Nucleus to Augment Wnt Signaling.

Peng L, Ye R, Zhu X, Xie Y, Zhong B, Liu Y, Li H, Xie B. Peng L, et al. Among authors: xie y, xie b. Biomed Res Int. 2022 Jan 28;2022:9631036. doi: 10.1155/2022/9631036. eCollection 2022. Biomed Res Int. 2022. PMID: 35132378 Free PMC article.

6

Elevated FAM134B expression induces radiation-sensitive in hepatocellular carcinoma.

Xie B, Xie Y, Fang C, Zhong B, Ye R, Zhang J, Liu Q, Li H. Xie B, et al. Among authors: xie y. BMC Cancer. 2023 Jul 17;23(1):671. doi: 10.1186/s12885-023-11030-x. BMC Cancer. 2023. PMID: 37460952 Free PMC article.

7

LncRNA SLC7A11-AS1 promotes the progression of hepatocellular carcinoma by mediating KLF9 ubiquitination.

Zeng FL, Lin J, Xie X, Xie YK, Zhang JH, Xu D, He X, Liu FE, Xie BH. Zeng FL, et al. Neoplasma. 2023 Jun;70(3):361-374. doi: 10.4149/neo_2023_230323N162. Neoplasma. 2023. PMID: 37498069

8

ACK1 promotes hepatocellular carcinoma progression via downregulating WWOX and activating AKT signaling.

Xie B, Zen Q, Wang X, He X, Xie Y, Zhang Z, Li H. Xie B, et al. Among authors: xie y. Int J Oncol. 2015 May;46(5):2057-66. doi: 10.3892/ijo.2015.2910. Epub 2015 Feb 27. Int J Oncol. 2015. PMID: 25738261

9

Angiogenesis and clinicopathologic characteristics in different hepatocellular carcinoma subtypes defined by EpCAM and α-fetoprotein expression status.

Shan YF, Huang YL, Xie YK, Tan YH, Chen BC, Zhou MT, Shi HQ, Yu ZP, Song QT, Zhang QY. Shan YF, et al. Med Oncol. 2011 Dec;28(4):1012-6. doi: 10.1007/s12032-010-9600-6. Epub 2010 Jun 23. Med Oncol. 2011. PMID: 20571936

10

SPRR3 Contributes to Aggressiveness of Pancreatic Cancer Cells via NF-κB Signaling Pathway.

Xie Y, Li H, Zhong B, Zhu X, Ye R, Xie B, Zhang J. Xie Y, et al. Among authors: xie b. Biomed Res Int. 2023 Jan 13;2023:7518744. doi: 10.1155/2023/7518744. eCollection 2023. Biomed Res Int. 2023. PMID: 36685674 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

26,222 results

Search Page

Filters